BioCentury
ARTICLE | Clinical News

JNJ-Q2: Phase II data

November 15, 2010 8:00 AM UTC

Top-line data from a double-blind, U.S. Phase II trial in 161 patients showed that twice-daily 250 mg oral JNJ-Q2 for 7-14 days missed the primary endpoint of non-inferiority to twice-daily 600 mg Zy...